Table 3.
Targeted therapies against oncogenic pathways in lung cancer
| Gene | Drug |
|---|---|
| AKT | MK-2206, Nelfinavir, Perifosine |
| ALK | Crizotinib, GSK1838705A, nVP-TAE684 |
| Aurora kinase | AZD 1152, MLN 8237, MK0457, MK5108 |
| BCL2 | ABT-737, Gossypol, Navitoclax (ABT-263), Oblimersen, Obatoclax |
| CDK | Purvalanol |
| COX-2 | Celecoxib |
| EGFR | AEE 788, AV-412, BMS-599626, BMS-690514, Canertinib, Cetuximab, CUDC-101EKB-569, Erlotinib, Gefitinib, Icotinib, Lapatinib, Matuzumab, Neratinib, Nimotuzumab, Panitumumab, Pelitinib, Vandetanib, XL647, Zalutumumab |
| ErbB2 | CI-1033, HKI-272, Lapatinib, Trastuzumab |
| FGFR | BIBF 1120, Brivanib Alaninate, E-7080, FP-1039, PD-173074, Regorafenib, TSU-68TKI-258, XL999 |
| FLT-3 | MK-0457, Sorafenib, Sunitinib, XL999 |
| FUS1 | fus1 liposome complex |
| HDACs | Belinostat, CUDC-101, Entinostat, Panobinostat, Pivanex, Romidepsin, SB939, Vorinostat |
| HER2 | AEE 788, Afatinib, AV-412, BMS-599626, BMS-690514, CUDC-101, EKB-569, Lapatinib, Neratinib, Pertuzumab, Trastuzumab, XL647, |
| Hh (SMO) | BMS-33923, Cyclopamine, GDC-0449, IPI-926, LDE 225 |
| HIF1 | Oncothyreon |
| HSP70 | 17-AAG |
| HSP90 | Alvespimycin, Retaspimycin, Tanespimycin |
| IAPs | HGS01029 |
| IGF-1R | AMG 479, BIIB022, BMS-754807, Cixutumumab, Figitumumab, MK-0646, OSI906 |
| c-KIT | AMG-706, Axitinib, Cediranib, Dasatinib, Imatinib, Motesanib, Pazopanib, Regorafenib, Sorafenib, Sunitinib, Vatalanib |
| MDM2 | JNJ-26854165, RO5045337 |
| MEK | AS 703026, AZD6244 (selumetinib), AZD8330, GDC-0973, GSK1120212, PD325901, RDEA119, Sorafenib |
| c-MET | AMG 102, AMG 208, ARQ197, Crizotinib, Foretinib, GSK1363089, PF-04217903, PHA-665752, SCH900105, SGX523, SU11274, XL184 |
| mTOR | AZD 8055, BEZ235, Everolimus, OSI 027, PX-866, Ridaforolimus, Sirolimus/Rapamycin, Temsirolimus |
| Notch (γ-secretase) | MK0752, MRK-003, PF03084014, RO 4929097 |
| p53 | p53 peptide vaccine, PRIMA-1 |
| PARP | AG014699, Iniparib, Olaparib, Veliparib |
| PDGFR | AMG-706, Axitinib, BIBF 1120, Cediranib, Dasatinib, E7080, Imatinib, IMC-3G3, Linifanib, Motesanib, Pazopanib, Ramucirumab, Regorafenib, Sorafenib, Sunitinib, TKI-258, TSU-68, Vatalanib, XL999 |
| PI3K | BEZ235, BGT226, GDC-0941, LY294002, PX-866, XL147, XL765 |
| PPARγ | BSI-201, CS 7017, Olaparib |
| Proteasome | Bortezomib, Carfilzomib, CEP-18770, MLN9708, Salinosporamide A |
| RAF | AZ628, GSK2118436, ISIS 5132, Regorafenib, Sorafenib, XL281 |
| RAS | lonafarnib, ISIS 2503 (H-Ras), Tipifarnib |
| SRC/BCR-ABL | AZD0530, Dasatinib, Imatinib, KX2-391, XL999 |
| Telomerase | Imetelstat, Sodium metaarsenite |
| TGF-β | Trabedersen |
| TRAIL | Apomab, Conatumumab, Dulanermin, Lexatumumab, Mapatumumab, rhApo2L |
| VEGF | Aflibercept, Bevacizumab |
| VEGFR | Adnectin, AEE 788, Axitinib, BIBF 1120, BMS-690514, Brivanib Alaninate, Cediranib, E7080, Foretinib, Linifanib, Motesanib, Neovasat, Pazopanib, Ramucirumab, Regorafenib, Sorafenib, Sunitinib, Tivozanib, TKI-258, TSU-68, Vandetanib, Vatalanib, XL184, XL647, XL999 |